COVID-19: Drugs in Development
The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.
Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.
Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.
| Company Name | Drug | Current Stage | Next Milestone | Collaboration | Last Updated |
|---|---|---|---|---|---|
|
Incyte Corporation INCY |
OLUMIANT |
Phase 3 trial of Olumiant in hospitalized participants with COVID-19, dubbed COV-BARRIER |
Results expected in December 2020 | Lilly | 10/19/2020 |
|
Incyte Corporation INCY |
Jakafi | Phase 3 trial of Jakafi in patients with COVID-19-associated Acute Respiratory Distress Syndrome who require mechanical ventilation (RUXCOVID-DEVENT) | 10/19/2020 | ||
|
Relief Therapeutics Holding AG (RLFTF. OB) |
RLF-100 | US Phase 2b/3 clinical trials of RLF-100 in respiratory deficiency due to COVID-19 | Topline data expected in Q4, 2020 | 10/13/2020 | |
| Altimmune Inc. | AdCOVID Intranasal Covid-19 vaccine | Positive results from the preclinical studies of AdCOVID announced on Jul.13 | Phase 1 clinical trial of AdCOVID in Q4 2020 | Vigene Biosciences, DynPort Vaccine Co. | 10/13/2020 |
| HUMANIGEN, INC | Lenzilumab | Phase III trial of Lenzilumab in severe and critical COVID-19 patients | Topline data expected in Q4, 2020 | 10/09/2020 | |
| Hepion Pharmaceuticals, Inc. | CRV431 | Preclinical stage | National Institute of Allergy and Infectious Diseases | 10/09/2020 |
Information and calendar provided by RTTnews.com.
For comments and feedback contact: editorial@rttnews.com
Article written by an RTT News Staff Writer, and posted on the RTT News.com website.
Article reposted on Markethive by Jeffrey Sloe